Best practice in assessing ototoxicity in children with cancer - PubMed (original) (raw)

Editorial

Best practice in assessing ototoxicity in children with cancer

Roderick Skinner. Eur J Cancer. 2004 Nov.

No abstract available

PubMed Disclaimer

Comment on

• Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.
  Li Y, Womer RB, Silber JH. Li Y, et al. Eur J Cancer. 2004 Nov;40(16):2445-51. doi: 10.1016/j.ejca.2003.08.009. Eur J Cancer. 2004. PMID: 15519518

Similar articles

• Cisplatin ototoxicity.
  Malhotra H. Malhotra H. Indian J Cancer. 2009 Oct-Dec;46(4):262-3. doi: 10.4103/0019-509X.55545. Indian J Cancer. 2009. PMID: 19749455 No abstract available.
• [Ototoxicity of drugs].
  Janczewski G, Goździk-Zołnierkiewicz T, Krauze A. Janczewski G, et al. Wiad Lek. 1995 Jan-Jun;48(1-12):125-31. Wiad Lek. 1995. PMID: 9638222 Review. Polish.
• Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.
  Riedemann L, Lanvers C, Deuster D, Peters U, Boos J, Jürgens H, am Zehnhoff-Dinnesen A. Riedemann L, et al. Pharmacogenomics J. 2008 Feb;8(1):23-8. doi: 10.1038/sj.tpj.6500455. Epub 2007 Apr 24. Pharmacogenomics J. 2008. PMID: 17457342
• [Drugs ototoxicity. Part II. Loop diuretics, nonsteroidal anti-inflammatory drugs, antineoplastic and antimalarial drugs ].
  Wrześniok D, Buszman E, Matusiński B. Wrześniok D, et al. Wiad Lek. 2003;56(7-8):369-74. Wiad Lek. 2003. PMID: 14969167 Review. Polish.
• Cisplatin ototoxicity in children: implications for primary care providers.
  Helt-Cameron J, Allen PJ. Helt-Cameron J, et al. Pediatr Nurs. 2009 Mar-Apr;35(2):121-7. Pediatr Nurs. 2009. PMID: 19472677 Review.

Cited by

• Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
  van As JW, van den Berg H, van Dalen EC. van As JW, et al. Cochrane Database Syst Rev. 2016 Sep 27;9(9):CD009219. doi: 10.1002/14651858.CD009219.pub4. Cochrane Database Syst Rev. 2016. PMID: 27669661 Free PMC article. Updated. Review.
• Cisplatin ototoxicity in rat cochlear organotypic cultures.
  Ding D, He J, Allman BL, Yu D, Jiang H, Seigel GM, Salvi RJ. Ding D, et al. Hear Res. 2011 Dec;282(1-2):196-203. doi: 10.1016/j.heares.2011.08.002. Epub 2011 Aug 12. Hear Res. 2011. PMID: 21854840 Free PMC article.
• Contribution of the GSTP1 c.313A>G variant to hearing loss risk in patients exposed to platin chemotherapy during childhood.
  Liberman PHP, Goffi-Gomez MVS, Schultz C, Jacob PL, de Paula CAA, Sartorato EL, Torrezan GT, Ferreira EN, Carraro DM. Liberman PHP, et al. Clin Transl Oncol. 2019 May;21(5):630-635. doi: 10.1007/s12094-018-1964-7. Epub 2018 Oct 25. Clin Transl Oncol. 2019. PMID: 30361796
• Platinum-induced hearing loss after treatment for childhood cancer.
  van As JW, van den Berg H, van Dalen EC. van As JW, et al. Cochrane Database Syst Rev. 2016 Aug 3;2016(8):CD010181. doi: 10.1002/14651858.CD010181.pub2. Cochrane Database Syst Rev. 2016. PMID: 27486906 Free PMC article. Review.
• Modulating the Activity of the Human Organic Cation Transporter 2 Emerges as a Potential Strategy to Mitigate Unwanted Toxicities Associated with Cisplatin Chemotherapy.
  Hucke A, Kantauskaite M, Köpp TN, Wehe CA, Karst U, Nedvetsky PI, Ciarimboli G. Hucke A, et al. Int J Mol Sci. 2024 Mar 2;25(5):2922. doi: 10.3390/ijms25052922. Int J Mol Sci. 2024. PMID: 38474165 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Medical

  • MedlinePlus Health Information